Monogram Technologies Adjusts FDA Update for mBôs TKA System

AUSTIN, TX / ACCESSWIRE / October 3, 2024 - Monogram Technologies Inc. has clarified a subtitle from its previous release concerning the FDA response to its mBôs TKA System. It emphasizes that the company has 180 days from receipt to provide additional data, rather than conducting a clinical trial within this period. This adjustment does not affect other details of the original October 2, 2024 release.

Monogram, listed as NASDAQ:MGRM, is advancing AI-driven robotics for orthopedic surgery. It aims to create scalable, patient-specific implants using 3D printing, AI, and robotics. The company has secured FDA clearance for mPress implants and seeks 510(k) clearance for robotic products but cannot anticipate clearance timelines.